The Manufacturers Life Insurance Company Takes Position in Repligen Corporation $RGEN

The Manufacturers Life Insurance Company purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the second quarter, HoldingsChannel.com reports. The fund purchased 38,172 shares of the biotechnology company’s stock, valued at approximately $5,208,000.

Other hedge funds also recently bought and sold shares of the company. United Capital Financial Advisors LLC purchased a new position in shares of Repligen during the 3rd quarter valued at $368,387,000. Opti Capital Management LP purchased a new stake in shares of Repligen in the fourth quarter worth $2,399,209,000. Maverick Capital Ltd. purchased a new stake in shares of Repligen in the first quarter worth $178,946,000. Wasatch Advisors LP bought a new stake in Repligen during the first quarter valued at $146,513,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Wells Fargo & Company raised their price target on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Repligen has an average rating of “Buy” and an average price target of $166.43.

Repligen Trading Up 2.7%

RGEN stock opened at $180.98 on Tuesday. The company has a market capitalization of $10.21 billion, a PE ratio of 247.92, a price-to-earnings-growth ratio of 3.22 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company’s 50 day moving average price is $153.08 and its two-hundred day moving average price is $133.28.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the prior year, the company earned $0.26 EPS. The firm’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.60% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.